Aug 12th, 2017 - As part of our coverage of the American Society of Hematology (ASH) Annual Meeting & Exposition, being held December 9–12 in Atlanta, we are speaking with Faith Davies, MD, about molecular remission in multiple myeloma. Dr. Davies is a professor of medicine and deputy director of the Myeloma Institute at the University of Arkansas for Medical Sciences in Little Rock. She is giving a talk titled...

May 12th, 2017 - As part of our coverage of the American Society of Hematology (ASH) Annual Meeting & Exposition held December 9–12 in Atlanta, we are speaking with Farhad Ravandi-Kashani, MD, professor of medicine and the chief of the section of developmental therapeutics in the department of leukemia at MD Anderson Cancer Center in Houston, about the management of patients with Philadelphia chromosome–positiv...

Dec 12th, 2017 - In this interview we discuss how a short diagnosis-to-treatment interval in newly diagnosed diffuse large B-cell lymphoma is associated with worse outcomes and how this could lead to trials favoring patients with a longer diagnosis-to-treatment interval and better expected outcomes.

Jul 12th, 2017 - As part of our coverage of the American Society of Hematology (ASH) Annual Meeting & Exposition held December 9–12 in Atlanta, we are speaking with Kieron Dunleavy, MD, about the latest strategies to treat primary mediastinal B-cell lymphoma (PMBCL). Dr. Dunleavy is a professor of medicine and the director of the lymphoma program at George Washington University Cancer Center in Washington, DC. ...